Ozempic for Weight Loss: Eligibility & Clinical Criteria

Ozempic (semaglutide) can be prescribed for weight loss when patients meet specific FDA criteria: BMI ≥30 or BMI ≥27 with weight-related comorbidities such as hypertension, type 2 diabetes, or obstructive sleep apnea. Prescription requires a formal medical evaluation and baseline assessment of cardiovascular and metabolic health.

Weight loss medication prescription is not automatic—it requires individualized clinical judgment. Understanding your eligibility, baseline health status, and how your body may respond to GLP-1 therapy can help you prepare for a meaningful conversation with your provider about whether semaglutide or alternative treatments align with your health goals.

FDA Criteria and Medical Eligibility for Semaglutide Weight Loss

The FDA approved semaglutide (Wegovy) for chronic weight management in 2021. Prescription requires BMI of 30 kg/m² or higher, or BMI of 27 kg/m² or higher with at least one weight-related condition. Your provider will assess your overall health history, current medications, and metabolic status before initiating therapy.

Eligibility is not limited to those with type 2 diabetes, though diabetic patients often qualify. Your provider evaluates personal and family history of thyroid cancer, pancreatitis, and cardiovascular disease. Blood work typically includes fasting glucose, lipid panel, and kidney function—essential baseline markers for safe GLP-1 use.

Clinical Evaluation Framework and Baseline Testing Requirements

Before prescription, your healthcare provider conducts a comprehensive assessment to establish baseline health metrics and identify contraindications. This evaluation determines not only whether you qualify, but also which GLP-1 formulation and starting dose may be most appropriate for your individual risk profile and treatment goals.

How Genetic Factors May Influence GLP-1 Therapy Response

Individual variation in GLP-1 receptor signaling and metabolic genes can influence how your body responds to semaglutide. Genetic variants in the GLP1R gene and related peptide-signaling pathways may affect weight loss magnitude, appetite suppression intensity, and side effect tolerance. These predispositions are not deterministic but can contextualize your response profile.

The Precision Peptide Genetic Test reveals predispositions in key peptide pathways—including GLP1R (rs6923761), GIPR (rs1800437), and metabolic genes like FTO (rs9939609) and MC4R (rs17782313). This genetic context may help you and your provider anticipate whether GLP-1 therapy aligns with your biology, and can guide dosing strategy or alternative peptide formulations if appropriate.

Prescription Options: Branded, Compounded, and Personalized Approaches

Once eligible, patients have multiple prescription pathways. Branded semaglutide (Ozempic for diabetes, Wegovy for weight loss) is FDA-approved but often carries higher out-of-pocket costs. Compounded semaglutide offers a regulated alternative sourced from licensed 503A pharmacies, typically at lower cost and with greater dosing flexibility for personalized titration.

Compounded semaglutide is formulated by state-licensed pharmacists under the same pharmaceutical standards as branded products, though compounded medications are not FDA-approved. Providers can adjust concentrations and delivery schedules to match your tolerance and response. Tirzepatide (dual GLP-1/GIP agonist) compounded formulations offer another option if single-agent GLP-1 monotherapy plateaus or causes limiting side effects.

Safety Considerations and Who Should Defer This Treatment

GLP-1 agonists are contraindicated in personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2). Caution is warranted in severe kidney disease, recent pancreatitis, diabetic retinopathy, or uncontrolled hypertension. Pregnancy is an absolute contraindication; women of childbearing age require reliable contraception during therapy.

Common side effects include nausea, vomiting, diarrhea, and constipation—usually transient during dose escalation. Rare but serious risks include pancreatitis, gallbladder disease, and retinal complications in those with existing diabetic retinopathy. Ongoing provider monitoring, including periodic clinical visits and lab work, is essential for safe long-term use.

How PlexusDx Supports a More Personalized Approach

PlexusDx integrates genetic predisposition data into the broader clinical eligibility picture. While your BMI and metabolic labs establish whether you meet FDA criteria, understanding your genetic background in peptide-signaling pathways may help provide context for how you might respond to GLP-1 therapy. This personalized approach supports a more informed conversation with your provider about whether semaglutide—or an alternative peptide formulation—aligns with your individual biology.

The Precision Peptide Genetic Test ($99 add-on or $298 standalone) reveals predispositions in GLP1R, GIPR, and metabolic genes. These variants should be interpreted with a qualified healthcare provider and do not predict your exact medication response. Instead, they offer a biological framework: for example, certain GLP1R variants may correlate with greater appetite suppression, while FTO and MC4R variants contextualize baseline metabolic rate and satiety sensitivity.

Armed with both your clinical baseline and genetic predisposition profile, you and your provider can make a more nuanced decision about starting dose, titration pace, and whether compounded semaglutide, tirzepatide, or a dual-peptide protocol (GLP-Squared) may best support your weight loss and metabolic goals. This data-driven personalization transforms weight loss from a one-size-fits-all approach into a precision-wellness strategy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Related Reading

• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Weight Loss Drugs Like Ozempic
• Ozempic Weight Loss Before And After Pictures